The protein complex AMP-activated protein kinase (AMPK) is believed to play an important role in the regulation of skeletal muscle glucose and lipid metabolism. Defects in the AMPK system might therefore be an important factor in the pathogenesis of type 2 diabetes. We aimed to identify genetic and environmental mechanisms involved in the regulation of AMPK expression and activity and to examine the association between AMPK protein levels and activity on the one hand, and glucose and fat metabolism on the other. We investigated skeletal muscle biopsies from 100 young and 82 older mono-and dizygotic nondiabetic twins excised during the basal and insulin-stimulated states of a physiological hyperinsulinemiceuglycemic clamp. AMPK␣1, -␣2, and -␥3 mRNA expression was investigated using real-time PCR, and Western blotting was employed to measure protein levels. Multiple regression analyses indicated that skeletal muscle AMPK mRNA and protein expression as well as activity were regulated by sex, age, obesity, and aerobic capacity. Comparison of intraclass correlations on AMPK measurements from mono-and dizygotic twins suggested that skeletal muscle AMPK expression was under minor genetic influence. AMPK␥3 protein expression and activity were negatively related to whole body glucose uptake through the nonoxidative metabolic pathway and positively related to phosphorylation of glycogen synthase. Our results suggest that skeletal muscle AMPK expression is under minor genetic control but regulated by age and sex and associated with obesity and aerobic capacity. Furthermore, our results indicate a role for ␥3-containing AMPK complexes in downregulation of insulin-stimulated nonoxidative glucose metabolism possibly through inhibition of glycogen synthase activity.
5Ј-adenosine monophosphate-activated protein kinase; heritability; glucose metabolism THE HETEROTRIMERIC PROTEIN COMPLEX AMP-activated protein kinase (AMPK) consists of a catalytic ␣-subunit and two regulatory (␤ and ␥) subunits. In mammalian cells, several isoforms of both the catalytic (␣1, ␣2) and regulatory subunits (␤1, ␤2, ␥1, ␥2, ␥3) have been identified. AMPK serves the role as a metabolic master switch in response to alterations in cellular energy status.
During metabolically stressed situations such as exercise, substrate deprivation, or hypoxia, the rise in the intracellular AMP/ATP ratio activates AMPK (15, 45) . Once activated, AMPK is known to restore cellular energy balance by stimulating catabolism through increased skeletal muscle glucose uptake and oxidation of fat (18, 22) and by inhibiting energyconsuming processes, including inhibition of glycogen synthesis through phosphorylation of glycogen synthase (GS) (17) . Additionally, in rodents, chronic AMPK activation by training (39) or pharmacologically induced energy deprivation (47) has been linked to regulation of mitochondrial biogenesis. Because of its central role in metabolic regulation, the AMPK system might be an important player in the pathogenesis of type 2 diabetes or be a future drug target in the treatment of type 2 diabetes. Previous studies have also shown that the two already existing antidiabetic drugs metformin and rosiglitazone activate AMPK in intact cells and in vivo (13, 14, 46) .
It is well known that genetic factors predispose to the development of type 2 diabetes (32, 34) . However, the rapidly increasing incidence of type 2 diabetes in recent years must be accounted for by environmental factors, of which obesity (20) , physical inactivity (37) , aging (11) , and the intrauterine environment as reflected by birth weight (33) all are accepted risk factors for type 2 diabetes. Previous studies have also identified gender as one of the major determinants of insulin sensitivity (24) .
Detailed knowledge of the regulatory mechanisms controlling skeletal muscle AMPK as well as the metabolic parameters regulated by AMPK is of great importance to fully understand the potential role of AMPK in the development and/or treatment of type 2 diabetes.
Therefore, we aimed to examine the influence of genetic and a range of nongenetic factors including sex, age, birth, and adult anthropometry as well as physical fitness on skeletal muscle AMPK expression by measuring ␣1, ␣2, and ␥3 mRNA and protein expression levels as well as ␥3 activity in biopsies from young and older monozygotic (MZ) and dizygotic (DZ) nondiabetic twins excised during the basal and insulin-stimulated state of a physiological hyperinsulinemiceuglycemic clamp. In addition, the association between skeletal muscle AMPK and in vivo measurements of oxidative and nonoxidative glucose metabolism (NOGM) was investigated.
MATERIALS AND METHODS

Subjects.
A random sample of same-sex young (25-32 yr) and older (58 -66 yr) MZ and DZ twin pairs (n ϭ 91 pairs) were identified through the Danish Twin Registry (30) . All subjects were healthy, without known diabetes, and born at term. Zygosity status was determined by polymorphic genetic markers (25) .
On the basis of a standard 75-g oral glucose tolerance test, three subjects with type 2 diabetes (all older) and 19 subjects with impaired glucose tolerance were identified on the basis of current WHO criteria (1) . All 91 twin pairs were included regardless of glucose tolerance status. The study was approved by the regional ethics committees and conducted according to the principles of the Helsinki Declaration.
Clinical examination. Subjects underwent a 2-day clinical examination separated by 1-2 wk. Twins within each twin pair were investigated simultaneously. Subjects were instructed to avoid strenuous physical activity for 24 h and to perform a 10-to 12-h overnight fast before both examination days. Measurements of anthropometry and body composition [dual-energy X-ray absorptiometry (DEXA) scan] were performed as described previously (30) . The subjects underwent a 2-h hyperinsulinemic-euglycemic clamp (40 mU ⅐ m Ϫ2 min Ϫ1 ). Steady state was defined as the last 30 min of the basal and clamp periods in which indirect calorimetry was performed in order to determine oxidation rates of glucose (Glcox) and fat (Fox) (31) .Basal and insulin-stimulated glucose turnover rates (R d) during the steadystate periods were calculated as previously described (30) .
Measurement of aerobic capacity. The maximal aerobic capacity (V O2 max) was estimated using an ergometer bicycle step test to exhaustion (5) .
Muscle biopsies and lysate preparation. Muscle biopsies were obtained from the vastus lateralis muscle under local anaesthesia (3-5 ml of Lidocaine) during the basal and insulin-stimulated steady-state periods using Bergström needle with suction applied. Biopsies were frozen in liquid nitrogen before being stored at Ϫ80°C. Muscle lysate preparation and total protein content measurements using a bicinchoninic acid assay (no. 23227; Pierce, Rockford, IL) were performed as described previously (34) .
AMPK and myosin heavy chain gene expression. Myosin heavy chain (MHC)7, MHCIIa, MHCIIx/d, and AMPK␣1, -␣2, and -␥3 gene expression levels were investigated using real-time PCR with an ABI 7900 system [Applied Biosystems (ABI), Foster City, CA]. Gene-specific probes and primer pairs were obtained from ABI (Assayson-Demand, MHC7: Hs00165276_m1, MHCIIa: Hs00430042_m1, MHCIIx/d: Hs00428600_m1, PRKAA1: Hs00178893_m1, PRKAA2: Hs00178903_m1, and PRKAG3: Hs00179660_m1). The transcript quantity was normalized to the mRNA level of cyclophilin A (Hs99999904_m1; ABI).
SDS-PAGE and Western blotting. AMPK␣1, -␣2, and -␥3 protein levels were measured using SDS-PAGE with Tris ⅐ HCl gels (Bio-Rad, Denmark) and Western blotting technique with PVDF membranes (Immobilion Transfer Membrane; Millipore, Denmark) and semidry transfer. AMPK protein levels were expressed relative to a human skeletal muscle control sample. AMPK␣1 and -␣2 protein contents were evaluated using primary antibodies raised in sheep (provided by Prof. D. G. Hardie, University of Dundee, UK), while AMPK␥3 protein level was evaluated using a primary antibody from Zymed Laboratories (cat. no. 52-5717). The phosphorylation of GS protein was determined on the following sites: site 2 (Ser 7 ), site 2 ϩ 2a (Ser 7/10 ), and site 3a ϩ 3b (Ser 640/644 ) as described previously (34) . AMPK activity assay. AMPK␥3 containing AMPK heterotrimeric complexes were immunoprecipitated in microtiter wells from 200 g of muscle lysate by use of protein G-agarose beads (Sigma-Aldrich, St. Louis, MO) and ␥3 isoform-specific AMPK antibody raised in sheep (provided by D. G. Hardie). Mixtures of lysate, antibody, and protein G beads were rotated end over end overnight at 4°C. After incubation, the immuniprecipitate (IP) was washed once in IP buffer, once in 480 mM HEPES (pH 7.0) and 240 mM NaCl, and twice in 240 mM HEPES (pH 7.0) and 120 mM NaCl, leaving 10 l of agarose after the last wash. The reaction ran for 30 min at 30°C in a total volume of 30 l containing 80 mM HEPES (pH 7.0), 40 mM NaCl, 833 M DTT, 200 M AMP, 100 M AMARA-peptide (Schafer-N, Denmark), 5 mM MgCl2, 200 M ATP, and 2 Ci of [␥- 33 P]ATP (PerkinElmer, Denmark). The reaction was stopped by adding 10 l of 1% phosphoric acid to the reaction, after which 20 l was spotted onto P81 filter paper (Whatman, GE Healthcare, Denmark), which was then washed four times for 15 min in 1% phosphoric acid. The dried filter paper was analyzed for activity using a Storm 850 PhosphorImager (Molecular Dynamics).
GS activity and glycogen content were determined as previously described (34) .
Statistical methods. Normal distribution was validated using the Kolmogorov-Smirnov goodness-of-fit test. Differences in AMPK expression before and after insulin stimulation were investigated using a paired t-test or the nonparametric Wilcoxon test where appropriate. Correlations were calculated using Pearson and Spearman correlation coefficients for normally distributed and skewed values, respectively.
To identify regulating factors of AMPK expression/activity and associations between AMPK protein levels/activity and measurements of glucose and fat metabolism, we performed multiple regression analyses using PROC MIXED for the SAS/STAT system (v. 9.1; SAS Institute, Cary, NC) with adjustment for intratwin pair relationships (adjusted P values are given as Padj). Residuals were always analyzed for normality to ensure that the outcome of the regression analyses was trustworthy.
Heritability. The extent to which MZ twins are more alike than DZ twins is presumed to reflect a genetic control on any given phenotype. The degree of similarity within MZ and DZ twin pairs is expressed by intraclass correlations (rMZ and rDZ, respectively) from which the heritability coefficient [h 2 ϭ 2(rMZ Ϫ rDZ)] can be calculated. Heritability expresses the proportion of the total variation of a trait attributable to genetic variation and ranges from 0 (trait exclusively under environmental control) to 1 (predominantly under genetic control). Statistical comparisons of intraclass correlations were made using the Fisher Z transformation (26) . P values Յ 0.05 were considered significant. Data are presented as means Ϯ SE.
RESULTS
Clinical and metabolic characteristics. In both young and older twins, men had significantly higher waist-to-hip ratio (WHR), fat-free mass (FFM), and V O 2 max and lower total fat mass and total fat percentage compared with women (Table 1) .
Glucose tolerance was similar in men and women in both age groups. Basal R d and insulin-stimulated Glc ox were higher in women than in men, and among the older subjects women had in addition a higher insulin-stimulated R d (Table 1) .
Influence of insulin on skeletal muscle AMPK expression. We compared skeletal muscle mRNA and protein expression levels of AMPK␣1, -␣2, and -␥3 during the basal and insulinstimulated periods of the hyperinsulinemic-euglycemic clamp. We found no significant influence of acute insulin infusion on ␣1, ␣2, or ␥3 gene expression, protein levels, or ␥3 activity. All the subsequent analyses were based on AMPK data during the basal state.
Genetic control of AMPK expression. The heritability estimates for skeletal muscle ␣1, ␣2, and ␥3 mRNA/protein expression and ␥3 activity were low, and intraclass correlations in MZ and DZ twins were similar, indicating that skeletal muscle AMPK expression is under minor genetic influence (Table 2) .
Association between skeletal muscle AMPK mRNA and protein expression levels, and activity. No correlation was seen between the mRNA and protein expression levels of AMPK␣1 (r ϭ Ϫ0.04, P ϭ 0.65) or AMPK␣2 (r ϭ 0.06, P ϭ 0.44). However, there was a significant correlation between AMPK␥3 mRNA and protein expression (r ϭ 0.48, P Ͻ 0.0001), as well as a significant correlation between ␥3 protein expression levels and ␥3 activity (r ϭ 0.52, P Ͻ 0.0001) (Fig. 1) .
Association between skeletal muscle fiber type and AMPK protein expression level. Neither AMPK␣1 nor -␣2 protein level correlated significantly with any MHC isoform mRNA levels. We found that AMPK␥3 protein level was negatively associated with MHC type 1 mRNA level (r ϭ Ϫ0.51, P Ͻ0.0001) and positively associated with MHC type 2a and 2x mRNA levels (r ϭ 0.23, P ϭ 0.002 and r ϭ 0.34, P Ͻ0.0001 for type 2a and 2x respectively; Fig. 2) .
Factors influencing skeletal muscle AMPK expression. The following putative explanatory factors of skeletal muscle AMPK␣1, -␣2, and/or -␥3 mRNA and/or protein expression and ␥3 activity were included in a multiple regression: total fat mass, V O 2 max , sex, age, zygosity, and birth weight (Table 3) . No influence of birth weight on AMPK expression/activity was demonstrated, why birth weight was not included in the final model. Due to the association with measurements of skeletal muscle fiber type, MHC mRNA proportions were additionally included as explanatory factors when investigating the regulation of AMPK␥3 mRNA, protein levels and activity.
Influence of sex on skeletal muscle AMPK expression and activity. Men had 41.6% higher ␣2 mRNA expression compared with women (men: 1.43 Ϯ 0.07, women: 1.01 Ϯ 0.06, P adj ϭ 0.003). This effect was dependent on age and only evident in young twins when stratified for age group. In the older group, men had 14.1% higher ␣2 protein levels compared with women, (men: 988 Ϯ 37, women: 866 Ϯ 32, P adj Ͻ 0.05). Men had 95.1% higher ␥3 gene expression (men: 1.58 Ϯ 0.09, women: 0.81 Ϯ 0.06, P adj Ͻ 0.0001) and 48.1% higher ␥3 protein level (men: 1,374 Ϯ 44, women: 928 Ϯ 40, P adj Ͻ 0.0001) than women. This sex difference was significant in both age groups. Finally, men also had 97.9% higher ␥3 activity than women (men: 0.16 Ϯ 0.014, women: 0.10 Ϯ 0.01, P adj ϭ 0.0001). This sex difference was significant in both age groups (Fig. 3) . The effects of sex on ␥3 mRNA/protein expression and activity were persistent upon adjustment for MHC mRNA proportions in the regression model.
Influence of age on skeletal muscle AMPK expression. Older twins had 40.6% lower ␥3 gene expression (young: 1.38 Ϯ 0.08, older: 0.92 Ϯ 0.05, P adj Ͻ 0.0001), 15.9% lower ␥3 protein levels (young: 1,182 Ϯ 47, older: 1,113 Ϯ 49, P adj Ͻ 0.05), and 47.7% lower ␥3 activity (young: 0.14 Ϯ 0.01, older: 0.11 Ϯ 0.01, P adj ϭ 0.003) than younger twins (Fig. 3) . When adjusting for MHC mRNA proportions, we found no effect of age on ␥3 protein level while effects on mRNA expression and activity level were still present.
Influence of zygosity on skeletal muscle AMPK expression. MZ twins had 21.8% higher ␣1 gene expression than DZ twins (MZ: 1.23 Ϯ 0.07, DZ: 1.01 Ϯ 0.05, P adj Ͻ 0.05). MZ twins had 22.0% higher ␣2 gene expression than DZ twins (MZ: 1.33 Ϯ 0.07, DZ: 1.09 Ϯ 0.06, P adj Ͻ 0.05).
Influence of obesity and aerobic capacity on skeletal muscle AMPK expression. Total fat mass related inversely to both ␣2 gene expression (P adj Ͻ 0.05) and ␥3 protein level (P adj Ͻ 
0.05).
In the multiple regression model, the effects of total fat mass were a 7.5% lower ␣2 gene expression and 6.5% lower ␥3 protein level per SD increase in total fat mass (1 SD for total fat mass being 7.8 kg). No relationship was found between total fat mass and ␥3 when adjustment for MHC mRNA proportions was performed. V O 2 max related inversely to both ␥3 gene expression (P adj Ͻ 0.01), ␥3 protein level (P adj ϭ 0.001), and ␥3 activity (P adj ϭ 0.003). The effects of V O 2 max were a 13.9% lower ␥3 gene expression, 13.9% lower ␥3 protein level, and 37.6% lower ␥3 activity per SD increase in V O 2 max (1 SD for V O 2 max being 9.9 ml ⅐kg Ϫ1 ⅐min Ϫ1 ) ( Table  3) . We found no relationship between V O 2 max and ␥3 mRNA/ protein levels when MHC mRNA proportions were included in the regression model, whereas a negative association with ␥3 activity was still present.
Association among skeletal muscle AMPK protein levels, ␥3 activity, and glucose/fat metabolism. Insulin-stimulated R d was inversely related to ␥3 protein expression (r ϭ Ϫ0.23, P Ͻ 0.01) and ␥3 activity (r ϭ Ϫ0.18, P ϭ 0.02) when we performed simple correlation analyses. However, when multiple regression analyses and adjusting for confounding variables were performed, ␣1, ␣2, or ␥3 protein expression and activity were not associated with basal or insulin-stimulated R d , Glc ox , or F OX . When multiple regression analysis was performed, insulin-stimulated NOGM was, on the other hand, negatively associated with both AMPK␥3 protein level (P adj Ͻ 0.01) and ␥3 activity (P adj ϭ 0.003). These effects were independent of total fat mass. The effect of ␥3 protein level was estimated as 9.5% reduction in insulin-stimulated NOGM per SD increase in ␥3 protein level (SD for ␥3 protein level being 39.3% of mean value), whereas the effect of ␥3 activity was estimated as a 5.5% reduction in insulin-stimulated NOGM per SD increase in ␥3 activity (SD for ␥3 activity being 0.1 pmol ⅐ min Ϫ1 ⅐ mg Ϫ1 ). In addition, AMPK␥3 protein levels correlated significantly with GS site 2 (r ϭ 0.21, P Ͻ 0.01) and site 3a ϩ 3b (r ϭ 0.19, P ϭ 0.01) phosphorylation. AMPK␥3 activity correlated significantly with GS site 2 (r ϭ 0.17, P ϭ 0.03), and a borderline significant association was found to site 2 ϩ 2a (r ϭ 0.14, P ϭ 0.08). We also found borderline negative associations between ␥3 activity and glycogen content (r ϭ Ϫ0.14, P ϭ 0.07) and GS activity (r ϭ Ϫ0.13, P ϭ 0.1), suggesting a possible link to glycogen synthesis.
DISCUSSION
In the present study of a large cohort of young and older twins, we demonstrate that skeletal muscle AMPK expression and activity were under minor genetic control, indicating a predominant regulation from nongenetic factors. Accordingly, we found that skeletal muscle AMPK expression and/or activity is regulated by age and sex and associated with obesity and aerobic capacity, whereas the intrauterine environment and physiological levels of insulin do not seem to play a major role in the regulation of AMPK. AMPK␥3 protein level and activity were negatively related to the nonoxidative pathway of glucose metabolism, perhaps through an ability of AMPK to inhibit GS activity by GS site 2, 2 ϩ 2a, and/or 3a ϩ 3b phosphorylation.
The classical twin approach represents a unique opportunity to evaluate the relative impact of genetic and environmental etiological components. The low heritability estimates of skeletal muscle AMPK␣1, -␣2, and -␥3 mRNA and protein ex- pression suggested a predominant nongenetic regulation. Accordingly, we demonstrate an influence of sex and age together with associations with obesity and aerobic capacity, whereas fetal environmental markers such as birth weight and zygosity were not major explanatory variables.
The expression of ␣2 and ␥3 subunits and ␥3 activity were significantly higher in men compared with women, with the sex difference being more pronounced for ␥3 than for ␣2. Most ␥3 proteins seem to be in AMPK complex with the ␣2 and ␤2 isoforms in human skeletal muscle (42) , suggesting a higher expression of ␣2␤2␥3 complex in male compared with female skeletal muscle. The ␣2␤2␥3 complex is the main AMPK complex in human skeletal muscle activated during exercise (3). Thus, previous observations that ␣2-associated AMPK activation after acute exercise is higher in men than in women (36) are in accord with our present results.
The lower ␥3 expression and activity in older compared with young twins found in this study are in accord with studies on rats demonstrating a negative relationship between age and exercise-induced ␣2-related AMPK activity (35) . In addition, we demonstrate that individuals with higher aerobic capacity have lower ␥3 mRNA, protein expression, and activity independent of sex, age, and obesity. One could argue that physical activity might also affect expression and/or activity of some skeletal muscle AMPK subunits, even in the absence of altered V O 2 max . Unfortunately, data on daily physical activity habits are not available on this cohort and could therefore not be included in the regression model. However, our findings are in accord with previous cross-sectional (27) and longitudinal studies (12, 42) based on much smaller human cohorts and suggest a shift from ␥3-to likely ␥1-containing AMPK complexes in human skeletal muscle after a period of exercise training. Interestingly, the effects of sex and V O 2 max were evident on both ␥3 gene expression and protein levels, which, together with their positive interrelationship, indicates that sex and V O 2 max might exert a regulatory effect on the ␥3 subunit at the transcriptional level.
In both rats (9) and humans (2), endurance exercise is known to cause a shift from fast-to slow-twitch skeletal muscle fibers. Thus, the negative relationship between V O 2 max and ␥3 expression/activity could indicate that expression/activity of ␥3-containing AMPK complexes is higher in fast-twitch fibers than in slow-twitch fibers, as suggested by previous studies on rodents (21) . The negative and positive correlations between ␥3 and type 1 and type 2a/2x mRNA levels respectively support the idea that expression of ␥3-containing AMPK complexes are higher in fast-twitch fibers. Our MHC mRNA data also suggest higher representation of slow-twitch fibers in women than in men and in older than in young twins (data not shown). Higher representation of slow-twitch fibers have also been reported in female subjects compared with males previously (36) and in older compared with young rats (19) . Thus, identified effects of sex, age, and V O 2 max on AMPK expression in this study might be associated with skeletal muscle fiber type composition. We found no effect of V O 2 max or age on ␥3 protein level when MHC mRNA proportions were included in the regression model, supporting the idea that the effect of V O 2 max and age might be directed through changes in the genetic programming controlling skeletal muscle fiber type. However, highly significant effects of sex on ␥3 mRNA, protein levels, and activity were persistent after adjustment for MHC mRNA proportions, indicating that sex differences in ␥3 expression and activity are, at least in part, independent of skeletal muscle fiber type.
The negative association between total body fat mass and skeletal muscle ␥3 protein level may seem somewhat paradoxical. However, this effect was not found on ␥3 activity level, and the estimated impact of total fat mass on ␥3 protein level was small compared with the effect by, e.g., V O 2 max and may be of minor importance. Accordingly, some studies have found similar ␣1 and ␣2 expression in skeletal muscle of obese and lean subjects (8, 40) . Nevertheless, other studies have reported attenuated exercise-stimulated AMPK activity in obese type 2 diabetic subjects compared with lean controls (38) , indicating that measurements of AMPK protein levels or activity in biopsies obtained during resting conditions might not be the optimal setup to unmask effects of obesity on the skeletal muscle AMPK system.
When investigating associations between AMPK protein levels/activity and metabolism, we saw a significant negative correlation between ␥3 protein level/activity and insulin-stimulated R d ; however, these associations did not reach statistical significance when we performed multiple regression analysis with adjustment for confounding variables. On the other hand, insulin-stimulated NOGM was independently and negatively related to both ␥3 protein level and activity, indicating that the putative effect of ␥3 complexes on R d could be through inhibition of the nonoxidative pathway of glucose metabolism.
In agreement with the proposed role of AMPK as a protector of cellular energy homeostasis (41) , it has previously been reported that AMPK phosphorylates GS both in vitro (4) and in vivo (17, 43) . Similarly, we found significant, positive associations between ␥3 protein/activity and GS sites 2 and 3a ϩ 3b phosphorylation as well as borderline significant associations to GS site 2ϩ2a. We also identified borderline significant negative associations between ␥3 activity and glycogen content and GS activity; supporting the idea that the ␥3 subunit might play a role in regulation of GS activity and potentially glycogen synthesis. Additional evidence of a regulatory role of AMPK on in vivo GS activity is the finding of a negative association between AMPK and GS activity in patients with McArdle's disease (28) and that mutations in the ␥3 The full model was: ln (AMPK expression/activity) ϭ age group ϩ sex ϩ total fat ϩ V O2max ϩ zygosity status. Directions of estimated effects are illustrated by arrows, and effects are expressed along with 95% confidence intervals (CI) per SD rise for continuous variables total fat and V O2max and as estimated difference between groups for class variables sex, age group, and zygosity.
gene cause glycogen accumulation in both human (6) and porcine muscle (23) . Nevertheless, the finding of similar AMPK expression (42) and activity (16, 42) in individuals with type 2 diabetes and controls indicates that AMPK is not the key regulatory kinase underlying the defective glycogen synthesis found in type 2 diabetic patients (7). High contents of skeletal muscle glycogen are also known to repress exercise-induced AMPK activity (44) . Thus, glycogen stores might also regulate ␥3 activity through a negative feedback mechanism.
The possibility that AMPK activation inhibits glycogen synthesis in vivo needs careful consideration when suggesting skeletal muscle AMPK as a future antidiabetic drug target. Fig. 3 . AMPK␣1 (A) and -␣2 (B) gene expression and protein levels and ␥3 (C) gene expression, protein levels, and activity stratified on age group and sex. Gene expression and protein levels are given in arbitrary units, while ␥3 activity is given in pmol ⅐ min Ϫ1 ⅐ mg Ϫ1 . Results are expressed as means Ϯ SE. *Padj Ͻ 0.05. P values were adjusted for total fat, V O2 max, sex, age group, and twin status.
However, activation of AMPK by 5-aminoimidazole-4-carboxamide-1-␤-D-ribofuranoside (AICAR) is known to normalize glycogen synthesis in insulin-resistant rat skeletal muscle (29) . This is probably due to AICAR's positive effect on glucose uptake (22) which might increase levels of intracellular glucose 6-phosphate (G-6-P) to a level where inhibitory phosphorylation of GS from AMPK might be overruled by allosteric activation of GS by G-6-P. The ␣2-containing AMPK complexes seem to be responsible for both AICAR-induced glucose uptake and site 2 phosphorylation of GS, but little is known about the distribution of regulatory ␤-and ␥-isoforms in these AMPK complexes (10, 21) . Thus, isoform composition-specific AMPK drug targeting might be a solution to avoid AMPK-induced effects on glycogen synthesis.
In conclusion, results from the present study suggest that human skeletal muscle AMPK expression and activity are under minor genetic control but regulated by age and sex and associated to obesity and aerobic capacity. We also demonstrate that AMPK␥3 protein level and activity were negatively related to insulin-stimulated nonoxidative glucose metabolism. This association might mechanistically be linked through the ability of ␥3-containing AMPK complexes to downregulate glycogen synthesis by phosphorylation of glycogen synthase at several sites.
